In this review article we have reported a series of hybrid compounds characterized by the presence of a α-halogenocryloyl alkylating moiety of low chemical reactivity, linked to known antitumor agents or their active moieties. Among them, brostallicin (PNU-166196), was selected for clinical development and is now undergoing Phase II studies in patients with advanced or metastatic soft tissue sarcoma. © 2009 Bentham Science Publishers Ltd.
alpha-Halogenoacrylic Derivatives of Antitumor Agents
ROMAGNOLI, Romeo;BARALDI, Pier Giovanni;PRETI, Delia
2009
Abstract
In this review article we have reported a series of hybrid compounds characterized by the presence of a α-halogenocryloyl alkylating moiety of low chemical reactivity, linked to known antitumor agents or their active moieties. Among them, brostallicin (PNU-166196), was selected for clinical development and is now undergoing Phase II studies in patients with advanced or metastatic soft tissue sarcoma. © 2009 Bentham Science Publishers Ltd.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
